The Patient Should NOT Be Taking a Steroid for Ear Fluid
Steroids are not recommended for otitis media with effusion (OME) based on current clinical practice guidelines, as they lack efficacy and do not improve meaningful outcomes.
Guideline-Based Recommendation
The American Academy of Otolaryngology—Head and Neck Surgery Foundation's 2016 clinical practice guideline explicitly emphasizes "the lack of efficacy for medical therapy (eg, steroids, antihistamines, decongestants)" for OME 1. This represents the highest quality evidence available and should guide clinical decision-making.
Why Steroids Are Not Recommended
The guideline development process reviewed extensive clinical trials and systematic reviews, concluding that:
- Oral steroids show no meaningful benefit for hearing outcomes or quality of life
- Most OME resolves spontaneously without intervention (90% of children experience at least one episode by age 2)
- The potential harms of systemic steroid exposure outweigh any marginal benefits
Evidence on Steroid Efficacy
Oral Steroids
A 2023 Cochrane review found that oral steroids (typically prednisolone for 7-14 days) 2:
- Probably result in little or no difference in the proportion of children with normal hearing after 12 months (69.7% vs 61.1% with placebo, RR 1.14)
- Show no difference in OME-related quality of life (moderate-certainty evidence)
- May reduce persistent OME at 6-12 months, but the clinical significance is uncertain and must be weighed against adverse effects
Intranasal Steroids
The evidence for nasal steroids (beclomethasone, fluticasone, mometasone) is even weaker 2:
- Very low-certainty evidence regarding hearing improvement
- Low-certainty evidence showing little to no effect on quality of life
- Uncertain effects on OME persistence
What the Patient Might Actually Be Taking
If a steroid was prescribed, it would most commonly be:
- Oral prednisolone (7-14 day course)
- Intranasal corticosteroids (fluticasone, mometasone, or beclomethasone for 2 weeks to 3 months)
However, this prescription contradicts current evidence-based guidelines 1.
Clinical Pitfalls to Avoid
- Do not prescribe steroids routinely for OME - the guideline explicitly recommends against this practice
- Educate patients about the favorable natural history of OME - most cases resolve within 3 months without intervention
- Focus on watchful waiting as the primary management strategy
- Consider intervention (tympanostomy tubes) only for chronic OME (≥3 months) with documented hearing loss or developmental concerns
Special Circumstances
The only scenario where steroids might be considered is intratympanic steroid injection as an adjunct to surgical intervention (myringotomy with ventilation tubes), but this is not standard practice and remains investigational 3, 4, 5. This would be administered by an otolaryngologist during a procedure, not prescribed as a take-home medication.
Bottom line: If the patient is taking a steroid for middle ear effusion, this represents non-evidence-based prescribing that should be discontinued and replaced with appropriate watchful waiting or, if indicated, surgical referral.